The prognosis of Ph+ ALL patients has dramatically improved upon the approval of BCR‐ABL tyrosine kinase inhibitor (TKI) imatinib mesylate as first‐line treatment. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.